Trastuzumab deruxtecan offers added benefit for patients with HER2-low breast cancer

[News]

The antibody-drug conjugate trastuzumab deruxtecan is approved for various therapeutic indications. Since March 2023, it can also be used as monotherapy for the treatment of adults with unresectable or metastatic HER2-low breast cancer who have received prior chemotherapy at this disease stage or developed disease recurrence early after adjuvant chemotherapy.

More... (https://www.news-medical.net/news/20231031/Trastuzumab-deruxtecan-offers-added-benefit-for-patients-with-HER2-low-breast-cancer.aspx)